Inhibition of vascular endothelial growth factor by small interfering RNA upregulates differentiation, maturation and function of dendritic cells

Wang,Haiyan; Zhang,Luping; Zhang,Shaoyan; Li,Yannian

doi:10.3892/etm.2014.2059

Inhibition of vascular endothelial growth factor by small interfering RNA upregulates differentiation, maturation and function of dendritic cells

Authors:
- Haiyan Wang
- Luping Zhang
- Shaoyan Zhang
- Yannian Li
View Affiliations

Affiliations: Department of Transfusion, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, Shandong 266033, P.R. China, Clinical Laboratory, Qingdao Hiser Hospital, Qingdao, Shandong 266033, P.R. China, Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, Shandong 266033, P.R. China
Published online on: November 11, 2014 https://doi.org/10.3892/etm.2014.2059
Pages: 120-124

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study aimed to investigate the effects of vascular endothelial growth factor (VEGF) secreted by MCF‑7 breast cancer cells on the differentiation, maturation and function of dendritic cells (DCs). Small interfering RNAs (siRNAs) directed against the VEGF gene were designed and transfected into MCF‑7 breast cancer cells at an optimal concentration (100 nmol/l) using cationic liposome transfection reagent, whereas the control group was transfected with only transfection reagent. Western blot analysis and ELISA were used to determine VEGF protein expression and VEGF concentration, respectively. Mononuclear cells were cultured with the culture supernatants from primary MCF‑7 cells (control group) and siRNA‑treated MCF‑7 cells (siRNA group). The DC phenotypes, including CD1a, CD80, CD83, CD86 and HLA‑DR, were evaluated by flow cytometry. The MTT assay was used to assess the cytotoxicity of DC‑mediated tumor‑specific cytotoxic T lymphocytes (CTLs) against MCF‑7 cells in the two different culture supernatants. The VEGF‑targeted constructed siRNA inhibited VEGF expression in MCF‑7 cells. Cultivation with the culture supernatants from MCF‑7 cells treated with siRNA affected DC morphology. DCs in the siRNA group exhibited a significantly higher expression of CD86, CD80, CD83 and HLA‑DR compared to the cells in the control group, whereas the expression of CD1a in the siRNA group was significantly lower compared to that in the control group. The cytotoxic activity of CTLs mediated by DCs was significantly altered by siRNA transfection. These results indicated that VEGF may play a significant role in tumor development, progression and immunosuppression.

View Figures

View References

1	Steinman RM and Cohn ZA: Identification of a novel cell type in peripheral lymphoid organs of mice. I Morphology, quantitation, tissue distribution. J Exp Med. 137:1142–1162. 1973. View Article : Google Scholar : PubMed/NCBI
2	Cella M, Sallusto F and Lanzavecchia A: Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol. 9:10–16. 1997. View Article : Google Scholar : PubMed/NCBI
3	Hart DN: Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 90:3245–3287. 1997.PubMed/NCBI
4	Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 9:271–296. 1991. View Article : Google Scholar : PubMed/NCBI
5	Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature. 392:245–252. 1998. View Article : Google Scholar : PubMed/NCBI
6	Baird JR, Fox BA, Sanders KL, et al: Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. Cancer Res. 73:3842–3851. 2013. View Article : Google Scholar : PubMed/NCBI
7	Schuler G and Steinman RM: Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med. 186:1183–1187. 1997. View Article : Google Scholar
8	Gabrilovich D, Ciernik F and Carbone DP: Dendritic cells in anti-tumor immune responses. I Defective antigen presentation in tumor-bearinghosts. Cell Immunol. 170:101–110. 1996. View Article : Google Scholar : PubMed/NCBI
9	Chaux P, Moutet M, Faivre J, Martin F and Martin M: Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab Invest. 74:975–983. 1996.PubMed/NCBI
10	Chaux P, Favre N, Martin M and Martin F: Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int J Cancer. 72:619–624. 1997. View Article : Google Scholar : PubMed/NCBI
11	Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D and Carbone DP: Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res. 3:483–490. 1997.PubMed/NCBI
12	Nestle FO, Burg G, Fah J, Wrone-Smith T and Nickoloff BJ: Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol. 150:641–651. 1997.PubMed/NCBI
13	Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA and Carbone DP: Dendritic cells in antitumor immune responses. II Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cell Immunol. 170:111–119. 1996. View Article : Google Scholar : PubMed/NCBI
14	Gabrilovich DI, Chen HL, Girgis KR, et al: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 2:1096–1103. 1996. View Article : Google Scholar : PubMed/NCBI
15	Ratta M, Fagnoni F, Curti A, et al: Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood. 100:230–237. 2002. View Article : Google Scholar : PubMed/NCBI
16	Um SH, Mulhall C, Alisa A, et al: Alpha-fetoprotein impairs APC function and induces their apoptosis. J Immunol. 173:1772–1778. 2004. View Article : Google Scholar : PubMed/NCBI
17	Péguet-Navarro J, Sportouch M, Popa I, et al: Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol. 170:3488–3494. 2003. View Article : Google Scholar : PubMed/NCBI
18	Sombroek CC, Stam AG, Masterson AJ, et al: Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol. 168:4333–4343. 2002. View Article : Google Scholar : PubMed/NCBI
19	Bockorny B and Dasanu CA: Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches. Expert Opin Biol Ther. 13:911–925. 2013. View Article : Google Scholar : PubMed/NCBI
20	Harimoto H, Shimizu M, Nakagawa Y, Nakatsuka K, Wakabayashi A, Sakamoto C and Takahashi H: Inactivation of tumor-specific CD8⁺ CTLs by tumor-infiltrating tolerogenic dendritic cells. Immunol Cell Biol. 91:545–555. 2013. View Article : Google Scholar : PubMed/NCBI
21	Toi M, Taniguchi T, Yamamoto Y, Kurisaki T, Suzuki H and Tominaga T: Clinical significance of the determination of angiogenic actors. Eur J Cancer. 32A:2513–2519. 1996. View Article : Google Scholar : PubMed/NCBI
22	Ellis LM and Fidler IJ: Angiogenesis and metastasis. Eur J Cancer. 32A:2451–2460. 1996. View Article : Google Scholar : PubMed/NCBI
23	Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997. View Article : Google Scholar : PubMed/NCBI
24	Salven P, Mänpää H, Orpana A, Alitalo K and Joensuu H: Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res. 3:647–651. 1997.PubMed/NCBI
25	Ni YH, Wang ZY, Huang XF, et al: Effect of siRNA-mediated downregulation of VEGF in Tca8113 cells on the activity of monocyte-derived dendritic cells. Oncol Lett. 3:885–892. 2012.PubMed/NCBI
26	Hajrasouliha AR, Funaki T, Sadrai Z, Hattori T, Chauhan SK and Dana R: Vascular endothelial growth factor-C promotes alloimmunity by amplifying antigen-presenting cell maturation and lymphangiogenesis. Invest Ophthalmol Vis Sci. 53:1244–1250. 2012. View Article : Google Scholar : PubMed/NCBI
27	Marti LC, Pavon L, Severino P, Sibov T, Guilhen D and Moreira-Filho CA: Vascular endothelial growth factor-A enhances indoleamine 2,3-dioxygenase expression by dendritic cells and subsequently impacts lymphocyte proliferation. Mem Inst Oswaldo Cruz. 109:70–79. 2014. View Article : Google Scholar :
28	Liu CZ, Zhang L, Chang XH, et al: Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer. Chin J Cancer Res. 24:130–137. 2012. View Article : Google Scholar
29	Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S and Muramatsu T: A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 64:3365–3370. 2004. View Article : Google Scholar : PubMed/NCBI
30	Walter S, Weinschenk T, Stenzl A, et al: Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 18:1254–1261. 2012. View Article : Google Scholar : PubMed/NCBI
31	Cubillos-Ruiz JR, Baird JR, Tesone AJ, et al: Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res. 72:1683–1693. 2012. View Article : Google Scholar : PubMed/NCBI
32	Gabrilovich DI, Ciernik IF and Carbone DP: Dendritic cells in antitumor immune responses. I Defective antigen presentation in tumor-bearing hosts. Cell Immunol. 170:101–110. 1996. View Article : Google Scholar : PubMed/NCBI
33	Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D and Carbone DP: Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res. 3:483–490. 1997.PubMed/NCBI
34	Gabrilovich DI, Chen HL, Girgis KR, et al: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 2:1096–1103. 1996. View Article : Google Scholar : PubMed/NCBI
35	Mosca PJ, Hobeika AC, Colling K, et al: Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand. J Leukoc Biol. 72:546–553. 2002.PubMed/NCBI
36	Scarlett UK, Rutkowski MR, Rauwerdink AM, et al: Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med. 209:495–506. 2012. View Article : Google Scholar : PubMed/NCBI
37	Gabrilovich DI, Chen HL, Girgis KR, et al: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 2:1096–1103. 1996. View Article : Google Scholar : PubMed/NCBI
38	Woltman AM and van Kooten C: Functional modulation of dendritic cells to suppress adaptive immune responses. J Leukoc Biol. 73:428–441. 2003. View Article : Google Scholar : PubMed/NCBI
39	Dikov MM, Ohm JE, Ray N, et al: Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol. 174:215–222. 2005. View Article : Google Scholar
40	Leung DW, Cachianes G, Kuang WJ, Goeddel DV and Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1306–1309. 1989. View Article : Google Scholar : PubMed/NCBI